HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy
These results suggest that ERBB2 mRNA expression, as measured by HER2DX, may help refine selection for T-chemo and guide more personalized treatment strategies in HER2-positive AGC.
Authors
- Glòria Fernández‐Esparrach (ORCID: https://orcid.org/0000-0002-3378-3940)
- M. Cuatrecasas
- Leonarda Di Candia (ORCID: https://orcid.org/0000-0003-0115-1153)
- L. Notario (ORCID: https://orcid.org/0009-0006-5116-8606)
- I. Méndez (ORCID: https://orcid.org/0009-0005-7381-8465)
- F. Brasó-Maristany
- E. Sanfeliu
- Tamara Saurí (ORCID: https://orcid.org/0000-0002-7479-5120)
- Laura Angelats (ORCID: https://orcid.org/0000-0002-0410-5470)
- T. Pascual
- Ismael Macías (ORCID: https://orcid.org/0009-0000-2093-3316)
- Alberto Indacochea (ORCID: https://orcid.org/0000-0003-2643-9807)
- David Pesántez
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Dulce Momblán
Institutions
- Breast Cancer Research Foundation (US)
- Hospital General de Granollers (ES)
- Hospital Clínic de Barcelona (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105563
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00